Evaluating the Benefits of Physiologic Insulin Delivery
NCT04416737
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Type 1 Diabetes
Interventions
DRUG:
Ultra-rapid insulin
Sponsor
Stanford University
Collaborators
[object Object]